HYPOTENSIVE AND ORGANOPROTECTIVE PROPERTIES OF TELMISARTAN, A MEMBER OF THE SARTAN GROUP OF ANTIHYPERTENSIVE DRUGS
Keywords:
Arterial hypertension (AH), arterial blood pressure (ABP), hypotensive agents, sartans, ARA, telmisartanAbstract
A regular increase in arterial pressure above normal levels, manifesting as arterial hypertension (AH) syndrome, occurs alongside cardiovascular diseases as well as other conditions. According to World Health Organization (WHO) analyses, AH is observed in 27% of the population over the age of 20. By 2025, this figure reached 29%. Among the population of Uzbekistan aged 40-60, AH was observed in 30.4% of cases. In this regard, there are numerous types of antihypertensive drugs used for AH, which are recommended to patients based on the mechanisms of blood pressure elevation and specific indications. This text examines the primary mechanisms of action of drugs belonging to the class of Angiotensin II receptor antagonists (ARAs), primarily telmisartan.
References
Mehta JK, Kaur G, Buttar HS, et al. Role of the renin-angiotensin system in the pathophysiology of coronary heart disease and heart failure: Diagnostic biomarkers and therapy with drugs and natural products. Front Physiol. 2023
Bhardwaj G. How the antihypertensive losartan was discovered. Expert Opin Drug Discov. 2006
Baguet JP, Robitail S, Boyer L, et al. A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Am J Cardiovasc Drugs. 2005
Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009
Wei J, Galaviz KI, Kowalski AJ, et al. Comparison of Cardiovascular Events Among Users of Different Classes of Antihypertension Medications: A Systematic Review and Network Meta-analysis. JAMA Netw Open. 2020
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018.
Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin- Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use? J Am Coll Cardiol. 2018
Конради А.О., Агеев Ф.Т., Галявич А.С., Карпов Ю.A., Кобалава Ж.Д., Котовская Ю.В., Недогода С.В., Недошивин А.О., Ткачева О.Н. Клиническое применение фиксированной комбинации телмисартана и индапамида для лечения артериальной гипертонии. Резолюция Совета Экспертов. Российский кардиологический журнал. 2025. (in Russ).
Rizaev A. Jhasur , Makhmonov S. Lutfulla , Gadaev G. Abdugaffor , Turakulov I. Rustam. Assessment of external factors involved in prediction of iron deficiency anemia associated with Helicobacter Pylori. Journal of Biomedicine and Practice. 2022, vol.7, issue 4, pp. 436-446
Rizaev , Zh ., & Yunuskhanova , K. (2021). Pathobiological interactions of rheumatoid arthritis and periodontal disease. Medicine and Innovation, 1(2), 37–40.
Mancia G, Kreutz R, Brunström M, et al. ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023.
Nurmamatovich E. O., Makhammatkulovich R. N., Shavkatovna S. S. MARKER TNF-308G/A IN PATIENTS WITH RELATIVE BLADDER CANCER //World Bulletin of Public Health. – 2023. – Т. 28. – С. 95-97.
Shavkatovna S. S., Makhammatkulovich R. N. FEATURES OF SARCOPENIA IN CANCER PATIENTS //EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE. – 2024. – Т. 4. – №. 8. – С. 286-292.
Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008.
